Comments on “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” by D’Amato et al.

Girolamo Adiletta,1 Stefano Baglioni,2 Germano Bettoncelli,3 Pierluigi Bracciale,4 Mario Cazzola,5 Enrico M. Clini,6 Renato Cutrera,7 Franco D’Adduzio,8 Francesco de Blasio,9,10 Fausto Ferraro,11 Roberto Fumagalli,12 Cosimo Lequaglie,13 Maria Gabriella Matera,14 Fabio Numis,15 Paolo Palange,16 Stefano Picciolo,17 Alfredo Potena,18 Francesco Romano,19 Eugenio Sabato,20 Antonio Sacchetta,21 Mario Spatafora,22 Francesco Stefanelli,23 Carlo Zottola24

1General Medicine, “Villa Malta” Hospital, Salerno
2Pneumology Department, Perugia Hospital
3General Practitioner, Brescia
4Pneumology Department, “Ninetto Melli” Hospital, San Pietro V.c (BR)
5Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome
6Respiratory Disease Unit, University Hospital of Modena and University of Modena Reggio Emilia
7Respiratory Unit, Academic Department of Pediatrics, Bambino Gesù Children’s Hospital, IRCCS, Rome
8UO Territorial Pneumology - ASL BT, Barletta (BT)
9Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center, Private Hospital, Naples
10Department of Medicine and Health Sciences ‘V. Tiberio’, University of Molise, Campobasso
11Department of Anesthetics, Surgical and Emergency Science, Second University of Naples
12Department of Medicine and Surgery, University of Milano Bicocca, Department of Anesthesia and Intensive Care, Ospedale Niguarda, Milan
13Department of Thoracic Surgery, IRCCS-CROB Centro Riferimento Oncologico Basilicata, Rionero in Vulture (PZ)
14Unit of Pharmacology, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples
15Emergency Department, Santa Maria delle Grazie Hospital, Naples
16Department of Clinical and Molecular Medicine, Division of Respiratory Diseases, Umberto I Hospital, Sapienza University, Rome
17Unit of Respiratory Medicine, Department of Medical Sciences, University Hospital of Messina
18General Medicine, Casa di Cura S.M. Maddalena Private Hospital, Occhiobello (RO)
19Respiratory Unit, Medical Center, Cosenza
20Pulmonology Ward, “A. Perrino” Hospital, Brindisi
21General Medicine, San Camillo Hospital, Treviso
22Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo (retired)
23Department of Pneumology, Monaldi Hospital, Naples
24Rehabilitation and Respiratory Section, INRCA-National Institute of Health and Sciences on Ageing, Cosenza, Italy

Correspondence: Francesco de Blasio, Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center, Private Hospital, Naples, Italy. E-mail: dicearchia@gmail.com

Key words: COVID-19; LMWH; steroids; home therapy.
Dear Editor,

We have read with interest the letter from D’Amato et al. entitled “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” [1], that aimed to demonstrate the usefulness of early use of prednisone and low molecular weight heparin (LMWH), in all patients with domiciliary SARS-CoV-2 infection, as a therapeutic strategy to reduce the risk of hospital admission. We are honestly surprised to read in your journal that you have accepted for publication such findings from a study that uses a therapeutic strategy which has not been approved by regulatory organisations and reports no evidence of approval from any local Ethical Committee. Indeed, these data refer to quarantined patients with mild symptoms with no indication to hospital admission by definition. To be more specific, none of the patients received neither physical medical examination, nor underwent any radiological confirmation of a possible disease progression with lung involvement. Finally, methodological weakness in study design (lack of control group with patients treated with symptomatic drugs only) precludes any firm conclusion among that we have read through the manuscript.

The letter content was echoed by a regional newspaper [2] and, as expected, immediately raised confusion and misunderstanding in the general public, mainly deriving from the discrepancies between what authors stated and what the medical communities advise nationwide. In fact, medical community (General Practitioners and even more specialists) are all following state-of-the-art guidelines that suggest the use of steroids only in patients with evidence of pneumonia with respiratory insufficiency [3-7], and LMWH in bed-bound patients with significant cardiovascular and metabolic comorbidities [8-12].

This also implicitly asserts the absolute need of a careful objective clinical evaluation to prevent any potentially dangerous misuse or overuse of medications.

We believe that in the pandemic era with several sources with misleading information, a scientific journal should not agree in helping confusion.

We hope that authors would be able to specify their beliefs to eventually favor a better understanding by the non-specialized press and social media.

References


Received for publication: 1 March 2021. Accepted for publication: 21 March 2021.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
©Copyright: the Author(s), 2021
Licensee PAGEPress, Italy
Multidisciplinary Respiratory Medicine 2021; 16:757